Rubicon Research: Business Overview & Financial Analysis
Rubicon Research Limited is a pharmaceutical products innovation and development enterprise headquartered in Mumbai, Maharashtra. Promoted by Dr. Pratibha Pilgaonkar, the company operates as a specialty pharmaceutical firm focusing on complex oral solid, liquid, ophthalmic, and injectable formulations. Operating advanced R&D centers and USFDA-inspected manufacturing plants in India, Rubicon Research develops, manufactures, and commercializes complex generic formulations, drug-device combinations, and novel drug delivery systems (NDDS) across regulated markets, including the US, Europe, and Canada.
Geographic Revenue Mix of Rubicon Research (FY26)
Rubicon Research derives the vast majority of its operational turnover from regulated export markets led by the United States.
- United States Market Share – 78.5% of Total Revenue
- European Union & UK Share – 12.2% of Total Revenue
- Canada & Other Regulated Geographies – 6.1% of Total Revenue
- India (Domestic Business & Out-Licensing) – 3.2% of Total Revenue
- Total Consolidated Revenue from Operations (FY26) – Rs 1,480.50 crore (+28.4% YoY)
The US healthcare market serves as the primary growth vector, driven by direct product launches and complex generic market share gains. European and Canadian distribution channels provide expanding revenue diversification across specialized formulation categories.
Dosage Form & Product Portfolio Mix of Rubicon Research (FY26)
Rubicon Research categorizes its formulation pipeline across oral solids, oral liquids, topicals, and sterile injectables.
- Oral Solid Dosages (Tablets & Capsules) – 54.0% of Total Revenue
- Oral Liquid Formulations & Suspensions – 24.0% of Total Revenue
- Ophthalmic & Otic Formulations – 12.0% of Total Revenue
- Injectables & Drug-Device Combinations – 10.0% of Total Revenue
Oral solids form the core revenue foundation, supported by extended-release and modified-release drug delivery platforms. High-margin oral liquids and sterile ophthalmic products represent fast-growing specialty segments within the commercial portfolio.
R&D Pipeline & Intellectual Property Scale of Rubicon Research (Q4 FY26)
Rubicon Research invests significantly in internal research and development to build a proprietary pipeline of Abbreviated New Drug Applications (ANDAs).
- Total Cumulative ANDA Filings with USFDA – 105 ANDA Filings
- Total USFDA Approved ANDAs – 68 Approved ANDAs
- Commercialized ANDA Products in US – 48 Active Commercial Products
- Cumulative Granted Patents Base – 120+ Patents Granted Worldwide
- Annual R&D Expenditure Share – 14.5% of Total Operating Revenue (FY26)
The company allocates over 14% of annual revenues to research operations, building an IP portfolio of 120+ granted patents. A commercialized portfolio of 48 approved ANDAs supports steady unit volume growth across US retail and institutional channels.
Global Manufacturing Facilities & USFDA Status of Rubicon Research (FY26)
Rubicon Research operates specialized manufacturing units and R&D facilities compliant with global regulatory standards.
- Primary Formulation Manufacturing Plant – Ambernath (Maharashtra, India)
- R&D Innovation Hub – Thane (Maharashtra, India)
- Specialized Oral Liquid & Sterile Facility – Satara (Maharashtra, India)
- Regulatory Compliance Status – USFDA, UK MHRA, and Health Canada Approved Facilities
- Plant Capacity Utilization Rate – ~72% across active processing lines
Manufacturing campuses in Ambernath and Satara supply high-volume commercial batches under strict cGMP protocols. Both units maintain clean regulatory records with USFDA and European health authorities following recent routine inspections.
Latest Quarterly Financial Performance of Rubicon Research (Q4 FY26)
Rubicon Research delivered strong top-line growth and operating EBITDA margin expansion during the fourth quarter of FY26.
- Consolidated Revenue from Operations – Rs 412.80 crore (+32.4% YoY)
- Consolidated Operating EBITDA – Rs 118.50 crore (+42.1% YoY)
- Consolidated Operating EBITDA Margin – 28.7% (+196 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 78.40 crore (+48.2% YoY)
- US Market Revenue Dispatches – $38.5 million (+29.8% YoY)
Fourth-quarter operating revenue rose 32.4% year-on-year to Rs 412.80 crore, driven by new ANDA product commercialization in the US. Consolidated Net Profit After Tax reached Rs 78.40 crore, while operating EBITDA margins expanded to 28.7%.
Consolidated Annual Financial Performance of Rubicon Research (FY26)
Rubicon Research achieved record operating turnover and net profitability for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 1,480.50 crore (+28.4% YoY)
- Full Year Operating EBITDA – Rs 418.20 crore (+36.5% YoY)
- Full Year Operating EBITDA Margin – 28.2% (+168 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 268.50 crore (+41.8% YoY)
- Total Return on Capital Employed (ROCE) – 24.8%
Full-year operating turnover crossed Rs 1,480 crore in FY26, as consolidated Net Profit After Tax expanded 41.8% to Rs 268.50 crore. Operational execution was supported by market share expansion in existing oral liquid ANDA products and lower batch manufacturing costs.
Balance Sheet Structure & Financial Ratios of Rubicon Research (Q4 FY26)
Rubicon Research maintains a conservative capital structure supported by operational cash flows and low debt exposure.
- Debt to Equity Ratio – Net Cash Positive / Low Debt (0.05x)
- Cash, Bank Balances & Surplus Investments – Rs 420 crore
- Return on Capital Employed (ROCE) – 24.8%
- Return on Equity (ROE) – 21.2%
- Working Capital Days – 78 days
The company closed FY26 with Rs 420 crore in cash reserves and a Net Debt to Equity ratio of 0.05x. Strong capital efficiency produced a Return on Capital Employed of 24.8%, funding internal R&D programs.
Expansion Roadmap & Capex Pipeline of Rubicon Research (FY27–FY28)
Rubicon Research executes strategic capital outlays to construct new sterile injectable blocks and expand oral solid processing lines.
- Annual Planned Capital Expenditure – Rs 180–220 crore per annum
- Satara Facility Expansion Outlay – Greenfield sterile injectable and ophthalmic manufacturing block
- Ambernath Plant Debottlenecking – Expanding oral solid tablet compression and coating capacities by 30%
- R&D Laboratory Upgrades – Investing in automated high-throughput analytical screening tools
- Funding Method – 100% funded via internal operational cash flows and IPO proceeds
Annual capex is budgeted at Rs 180–220 crore to build a dedicated sterile injectable unit at Satara and expand tablet capacity at Ambernath. All expansion projects are funded through internal cash generation and equity proceeds without long-term debt reliance.
Management Commentary & Strategic Outlook of Rubicon Research (Q4 FY26 / FY27)
Management guidance outlines strategic priorities centered on ANDA filing acceleration, complex formulation development, and margin expansion.
- Management targets maintaining a top-line revenue CAGR of 20%–25% over the FY27–FY29 period.
- Annual ANDA filing rate is targeted at 12–15 new filings per year with the USFDA.
- Operating EBITDA margins are guided to sustain within the 27.5%–29.5% corridor through product mix enrichment.
- Injectable and ophthalmic segment share is projected to reach 20% of overall sales over the next 3 years.
- R&D expenditure will be sustained at 12%–14% of annual turnover to support NDDS and complex generic development.
Management anticipates steady demand for complex generics and niche formulation products across North American and European health systems. Operational focus centers on filing high-value ANDAs, completing Satara plant expansions, and deepening commercial partnerships in regulated geographies.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Rubicon Research Limited Annual Report FY26 (July 2026)
- Rubicon Research Limited Q4 & Full Year FY26 Consolidated Financial Disclosures (May 2026)
- National Stock Exchange of India (NSE) & BSE Limited Corporate Filings for Rubicon Research Limited
- Ticker Finology Rubicon Research Page
Disclaimer
The information presented above on Rubicon Research Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Rubicon Research Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.